Trial reportThe international journal of neuropsychopharmacology2014
Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.
Trial report in The international journal of neuropsychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Pooled it
- International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators.Molecular psychiatry · 2022Pooled it
- Efficacy of ketamine for major depressive episodes at 2, 4, and 6-weeks post-treatment: A meta-analysis.Psychopharmacology · 2021Pooled it
- High Baseline Plasma Anthranilic Acid Predicts Remission Upon Acute-Series Ketamine Infusion for Treatment-Resistant Depression.Biological psychiatry global open science · 2025Article
- Use of Ketamine in Patients with Multifactorial Neuropathic Pain: A Systematic Review and Meta-Analysis.Pharmaceuticals (Basel, Switzerland) · 2024Review
- EEG-vigilance regulation is associated with and predicts ketamine response in major depressive disorder.Translational psychiatry · 2024Article
- Review
- Retracing our steps to understand ketamine in depression: A focused review of hypothesized mechanisms of action.The mental health clinician · 2021Review
- Role of Ketamine in the Treatment of Psychiatric Disorders.Health psychology research · 2021Review
- Neurobiological biomarkers of response to ketamine.Advances in pharmacology (San Diego, Calif.) · 2020Review
- Treatment for Substance Use Disorder With Co-Occurring Mental Illness.Focus (American Psychiatric Publishing) · 2019Review
- Interaction of Sex and Age on the Dissociative Effects of Ketamine Action in Young Healthy Participants.Frontiers in neuroscience · 2019Article
- The Effect of Glutamatergic Modulators on Extracellular Glutamate: How Does this Information Contribute to the Discovery of Novel Antidepressants?Current therapeutic research, clinical and experimental · 2019Review
- Major Depression and the Degree of Suicidality: Results of the European Group for the Study of Resistant Depression (GSRD).The international journal of neuropsychopharmacology · 2018Article
- Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder.International journal of environmental research and public health · 2018Review
- Efficacy of Ketamine in the Treatment of Substance Use Disorders: A Systematic Review.Frontiers in psychiatry · 2018Review
- A review of ketamine's role in ECT and non-ECT settings.Neuropsychiatric disease and treatment · 2018Review
- The antidepressant efficacy of subanesthetic-dose ketamine does not correlate with baseline subcortical volumes in a replication sample with major depressive disorder.Journal of psychopharmacology (Oxford, England) · 2017Article
- Experimental medication treatment approaches for depression.Translational psychiatry · 2017Review
- Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion.Journal of affective disorders · 2017Review
Corrections and comments
- Erratum issuedErratum.2016
Authors and funding
9 authors.
Funding
Abstract
backgroundA single subanesthetic infusion of the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine has rapid and potent antidepressant properties in treatment-resistant major depressive disorder (TRD). As a family history of an alcohol use disorder is a positive predictor of ketamine's antidepressant response and the strength of the association increases over time, we hypothesized that depressed subjects with a family history of an alcohol use disorder would have greater antidepressant durability and that riluzole would augment and/or extend ketamine's antidepressant efficacy.
methodsFifty-two TRD subjects received an open-label infusion of ketamine (0.5mg/kg over 40 minutes), and, four to six hours post-infusion, were randomized to either flexible-dose (100-200mg/day) riluzole or placebo in the following proportions: Family History Positive (FHP) riluzole (n = 10), FHP placebo (n = 9), Family History Negative (FHN) riluzole (n = 16), and FHN placebo (n = 17).
resultsFHP subjects randomized to placebo had a greater antidepressant response than FHN subjects; however, contrary to our initial hypothesis, there was no significant difference in antidepressant efficacy with riluzole. Although potentially underpowered, there was no difference in overall time-to-relapse based on randomization status (riluzole responders: n = 15, placebo responders: n = 17). Yet, time-to-relapse was longer in FHP placebo responders (n = 8) compared to FHN placebo responders (n = 9) with, again, no significant difference in time-to-relapse in FHP riluzole responders (n = 6) compared to FHN riluzole responders (n = 9).
conclusionsKetamine's extended antidepressant durability in FHP TRD should be considered in the design and analysis of ketamine depression trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.